In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kura Oncology (KURA), with a price target of $31. The company’s shares opened today at $13.08.
Pantginis wrote:
“Valuation and impediments to achieving price target. We reiterate our Buy rating and $31 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”
According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -16.9% and a 28.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
Currently, the analyst consensus on Kura Oncology is a Strong Buy with an average price target of $31.50, representing a 140.8% upside. In a report issued on November 28, Oppenheimer also assigned a Buy rating to the stock with a $32 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.03 and a one-year low of $10.20. Currently, Kura Oncology has an average volume of 259.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
